A UK PRISM phase 2 trial revealed that a modified regimen of ipilimumab every 12 weeks, combined with nivolumab, reduced serious adverse events in patients with advanced clear cell renal cell carcinoma. Involving 192 patients, the study compared this modified regimen to the standard approach and found a lower incidence of grade ≥3 adverse events in the modified group. Although it didn’t meet the efficacy threshold for 12-month progression-free survival, the rates were similar between both groups, indicating fewer side effects without sacrificing efficacy.
Reference: Stenger M. Modified vs Standard Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma. The ASCO Post. Updated December 15, 2023. Accessed December 20, 2023. https://ascopost.com/news/november-2023/modified-vs-standard-ipilimumab-plus-nivolumab-in-advanced-renal-cell-carcinoma/
